ALB and Cirrhosis: This analysis evaluated the theoretical cost-effectiveness of albumin in the treatment of decompensated cirrhosis requiring LVP, with SBP, or with HRS, across 3 European countries, Germany, Italy, and Spain, from a hospital perspective.